Cargando…
Challenges in lung cancer therapy during the COVID-19 pandemic
Autores principales: | Calabrò, Luana, Peters, Solange, Soria, Jean-Charles, Di Giacomo, Anna Maria, Barlesi, Fabrice, Covre, Alessia, Altomonte, Maresa, Vegni, Virginia, Gridelli, Cesare, Reck, Martin, Rizvi, Naiyer, Maio, Michele |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7146673/ https://www.ncbi.nlm.nih.gov/pubmed/32278368 http://dx.doi.org/10.1016/S2213-2600(20)30170-3 |
Ejemplares similares
-
Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study
por: Calabrò, Luana, et al.
Publicado: (2021) -
COVID and Lung Cancer
por: Calabrò, Luana, et al.
Publicado: (2021) -
A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation
por: Maio, Michele, et al.
Publicado: (2021) -
Deciphering the response and resistance to immune-checkpoint inhibitors in lung cancer with artificial intelligence-based analysis: when PIONeeR meets QUANTIC
por: Ciccolini, Joseph, et al.
Publicado: (2020) -
Immunotherapy of brain metastases: breaking a “dogma”
por: Di Giacomo, Anna Maria, et al.
Publicado: (2019)